Treating Alzheimer's with aspirin
Low-dose aspirin regimen could reduce Alzheimer's disease pathology
- Date:
- July 2, 2018
- Source:
- Society for Neuroscience
- Summary:
- A low-dose aspirin regimen may represent a new avenue for reducing Alzheimer's disease pathology, according to new research in a mouse model. The study identifies a new role for one of the most widely used medications in the world.
- Share:
A low-dose aspirin regimen may represent a new avenue for reducing Alzheimer's disease pathology, according to new research in a mouse model of the disease published in JNeurosci. The study identifies a new role for one of the most widely used medications in the world.
Although the exact cause of Alzheimer's disease progression is unknown, impaired clearance of toxic amyloid beta, especially from the hippocampus, is a leading mechanism. Activating the cellular machinery responsible for removing waste from the brain has therefore emerged as a promising strategy for slowing the disease.
Building on studies demonstrating a link between aspirin and reduced risk and prevalence of Alzheimer's disease, Kalipada Pahan and colleagues show that this common over-the-counter medication decreases amyloid plaque pathology in mice by stimulating lysosomes -- the component of animal cells that help clear cellular debris. The research adds to aspirin's established uses for pain relief and for the treatment of cardiovascular diseases.
Story Source:
Materials provided by Society for Neuroscience. Note: Content may be edited for style and length.
Journal Reference:
- Sujyoti Chandra, Malabendu Jana, Kalipada Pahan. Aspirin induces Lysosomal biogenesis and attenuates Amyloid plaque pathology in a mouse model of Alzheimer's disease via PPARα. The Journal of Neuroscience, 2018; 0054-18 DOI: 10.1523/JNEUROSCI.0054-18.2018
Cite This Page: